Wockhardt reported strong Q1 FY27 results: PAT Rs. 107 Cr, revenue up 26% to Rs. 929 Cr, EBITDA up 86%. Biotech operations surged 112%. US FDA approved Zaynich for cUTI, a landmark for an India-discovered drug.

Wockhardt LimitedWOCKPHARMA · Filed with the exchange